8/102 sources · 2 publishersUpdated Oct 8, 15:51 UTC
Novartis signs $575 million upfront licensing deal with Abogen Biosciences
Novartis announced a licensing and option agreement with Abogen Biosciences that provides an upfront cash payment of $575 million and grants worldwide rights to ABO2203, an mRNA‑encoded T‑cell engager for autoimmune diseases. The contract also includes options for additional RNA platform programs and potential milestone payments of up to $7.2 billion. The deal was disclosed on October 2 2026.
Why it matters
The company expects the upfront payment to strengthen its cash position while the large milestone potential could add significant future revenue if development milestones are met, according to the announcement (material [1]).
Key facts
- 1Novartis will pay $575 million upfront to Abogen Biosciences. gurufocus.com
- 2The agreement provides for up to $7.2 billion in milestone payments. gurufocus.com
- 3The deal grants Novartis worldwide rights to ABO2203, an mRNA‑encoded T‑cell engager targeting autoimmune diseases. gurufocus.com
- 4The licensing and option agreement was announced on October 2 2026. gurufocus.com
- 5Novartis stock was trading around $140.28 at the time of the announcement. rttnews.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.